MX2023000951A - Aplicaciones 5' s/mar. - Google Patents

Aplicaciones 5' s/mar.

Info

Publication number
MX2023000951A
MX2023000951A MX2023000951A MX2023000951A MX2023000951A MX 2023000951 A MX2023000951 A MX 2023000951A MX 2023000951 A MX2023000951 A MX 2023000951A MX 2023000951 A MX2023000951 A MX 2023000951A MX 2023000951 A MX2023000951 A MX 2023000951A
Authority
MX
Mexico
Prior art keywords
polynucleotides
promoter
expression constructs
mar
relates
Prior art date
Application number
MX2023000951A
Other languages
English (en)
Inventor
Richard Harbottle
Matthias Bozza
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of MX2023000951A publication Critical patent/MX2023000951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

La presente invención se refiere a una célula terapéutica que comprende un polinucleótido episomal que comprende un promotor y una secuencia expresable, en donde dicho polinucleótido episomal comprende además un elemento S/MAR corriente arriba de dicho promotor. La presente invención además se refiere a constructos de expresión, polinucleótidos, células hospederas de animales, constructos de expresión, vectores y/o polinucleótidos que comprenden una secuencia de carga relacionada con los mismos.
MX2023000951A 2020-07-22 2021-07-21 Aplicaciones 5' s/mar. MX2023000951A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20187240 2020-07-22
PCT/EP2021/070403 WO2022018143A1 (en) 2020-07-22 2021-07-21 5' s/mar applications

Publications (1)

Publication Number Publication Date
MX2023000951A true MX2023000951A (es) 2023-04-03

Family

ID=71741717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000951A MX2023000951A (es) 2020-07-22 2021-07-21 Aplicaciones 5' s/mar.

Country Status (10)

Country Link
US (1) US20230293690A1 (es)
EP (1) EP4185692A1 (es)
JP (1) JP2023537858A (es)
KR (1) KR20230041741A (es)
CN (1) CN116209767A (es)
AU (1) AU2021311027A1 (es)
CA (1) CA3186837A1 (es)
IL (1) IL300077A (es)
MX (1) MX2023000951A (es)
WO (1) WO2022018143A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19848017A1 (de) 1998-10-17 2000-04-20 Multigene Biotech Gmbh Episomal replizierender Vektor zur Expression eines Transgens in Säugerzellen
WO2005005644A1 (en) * 2003-07-11 2005-01-20 Cytos Biotechnology Ag Gene expression system
WO2019057774A1 (en) 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
ES2821655T5 (es) 2017-09-19 2024-08-06 Deutsches Krebsforsch Vectores de ADN no integrantes para la modificación genética de células
CN107868781A (zh) * 2017-11-15 2018-04-03 新乡医学院 人工合成mar片段、表达载体、表达系统及其应用

Also Published As

Publication number Publication date
CN116209767A (zh) 2023-06-02
WO2022018143A1 (en) 2022-01-27
IL300077A (en) 2023-03-01
CA3186837A1 (en) 2022-01-27
KR20230041741A (ko) 2023-03-24
US20230293690A1 (en) 2023-09-21
AU2021311027A1 (en) 2023-03-02
JP2023537858A (ja) 2023-09-06
EP4185692A1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
MX2019007233A (es) Polipetidos que tienen actividad lisozima, polinucleótidos que codifican para los mismos y usos y composiciones de los mismos.
MX2022006427A (es) "construcciones para terapia génica con microdistrofina y uso de las mismas.
MX2020004578A (es) Composiciones de casz y metodos de uso.
WO2018226964A3 (en) Promoters from corynebacterium glutamicum and uses thereof in regulating ancillary gene expression
MX2019013227A (es) Polipeptidos que tienen actividad de lisozima, polinucleotidos que los codifican y usos y composiciones de los mismos.
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
RS50488B (sr) Vektori ekspresije koji sadrže mcmv ie2 promotor
MX2020003092A (es) Vectores de adn no integrantes para la modificacion genetica de celulas.
MX2018005886A (es) Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias.
CO6160247A2 (es) Variantes de pululanasa con productividad elevada y metodos para prepararlas
CA3057899A1 (en) Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
EA202193139A1 (ru) Вирусные векторы и их применение в адоптивной клеточной терапии
WO2020079034A3 (en) Intein proteins and uses thereof
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
MX2020008676A (es) Expresion controlada de transgenes mediante el uso de vectores de adn de extremo cerrado (ceadn).
MX2019011900A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
WO2022074037A3 (en) Alpha-amylase variants
AU2017384228A8 (en) Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
MX2023005876A (es) Sistema de vector para administracion de multiples polinucleotidos y usos del mismo.
BR112016016014A2 (pt) gene resistente a inseto derivado de ser humano e anticorpo de cadeia única de idiotipo de toxina anti-cry1b codificado pelo mesmo e aplicação do mesmo
MX2021005555A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.
MX2023000951A (es) Aplicaciones 5' s/mar.
MX2022005644A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.